agreed. the 2 problems were (i) Amarex was / is a terrible CRO, and (ii) we hired Amarex, loved them for a long time, and missed the fact that they were mis-managing the most important initiative for the company until it was too late.

absent either of these 2 faults and we'd have an approved drug and probably be at $5-10 right now with cash in the bank (and rich shareholders).